The affinity of canakinumab to interleukin-1 beta granted this mAb FDA approval for potent inflammatory conditions including cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (SJIA) [217]. Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.